Jeremy Grantham Cytom X Therapeutics, Inc. Transaction History

Grantham, Mayo, Van Otterloo & Co. LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2021 May 13, 2021	SELL	$6.6 - $9.0 $759,554 - $1.04 Million	-115,084 Closed	0 $0
Q4 2020 Feb 12, 2021	SELL	$6.47 - $7.9 $714,391 - $872,286	-110,416 Reduced 48.96%	115,084 $754,000
Q3 2020 Nov 13, 2020	BUY	$6.55 - $8.83 $484,700 - $653,420	74,000 Added 48.84%	225,500 $1.5 Million
Q2 2020 Aug 13, 2020	BUY	$7.4 - $14.64 $980,500 - $1.94 Million	132,500 Added 697.37%	151,500 $1.26 Million
Q1 2020 May 14, 2020	BUY	$3.61 - $8.6 $68,590 - $163,400	19,000 New	19,000 $146,000
Q3 2018 Nov 14, 2018	SELL	$18.04 - $26.41 $268,796 - $393,509	-14,900 Closed	0 $0
Q4 2017 Feb 14, 2018	BUY	$19.0 - $23.09 $283,100 - $344,041	14,900	14,900 $315,000

49.4M

112K

8.3K

Ticker CTMX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 65,950,200
Market Cap $55.4M
Description
CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops antibody therapeutics based on its Probody technology platform for the treatment of cancer. The company's product candidates include CX-2009, an antibody drug conjugates (ADC) against CD166, which is in Phase II clinical...

Get notified when there are updates to the investment portfolio of Grantham, Mayo, Van Otterloo & Co. LLC, based on Form 13F filings with the SEC.

Stay updated on Grantham, Mayo, Van Otterloo & Co. LLC and Jeremy Grantham with notifications on news.